| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/30/2009 | WO2009093747A1 Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them |
| 07/30/2009 | WO2009093737A1 Anti-obesity pharmaceutical composition |
| 07/30/2009 | WO2009093735A1 Pharmaceutical composition |
| 07/30/2009 | WO2009093713A1 Peg-modified hydroxyapatite, pharmaceutical preparation containing the same as base material, and method for production of the same |
| 07/30/2009 | WO2009093650A1 Prostaglandin-containing fat emulsion and method for producing the same |
| 07/30/2009 | WO2009093638A1 PROCESS FOR PRODUCTION OF β-LACTAM COMPOUND |
| 07/30/2009 | WO2009093595A1 Method for producing carotenoid-containing emulsion composition, carotenoid-containing emulsion composition obtained by the same, carotenoid-containing powder composition, and functional food and cosmetic preparation each containing the composition |
| 07/30/2009 | WO2009093534A1 Vegfc production promoter |
| 07/30/2009 | WO2009093471A1 Apoptosis inhibitor |
| 07/30/2009 | WO2009093463A1 Neuronal cell death inhibitor |
| 07/30/2009 | WO2009093454A1 Food composition, feed composition comprising the food composition, and method for feeding animal by using the feed composition |
| 07/30/2009 | WO2009093384A1 Polynucleotide or analogue thereof, and gene expression regulation method using the polynucleotide or the analogue thereof |
| 07/30/2009 | WO2009093353A1 Medicinal composition |
| 07/30/2009 | WO2009093269A1 Novel heterocyclic compounds |
| 07/30/2009 | WO2009093264A2 Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. |
| 07/30/2009 | WO2009093259A2 A PROCESS FOR PRODUCING γ-MANGOSTIN |
| 07/30/2009 | WO2009093255A2 A new nutraceutical composition from garcinia mangostana |
| 07/30/2009 | WO2009093253A2 Compositions and methods for modulating vascular endothelial growth factor c (vegf-c) expression |
| 07/30/2009 | WO2009093207A1 Composition for topical use |
| 07/30/2009 | WO2009093144A2 Photodynamic therapy of sebaceous gland disorders |
| 07/30/2009 | WO2009093049A1 Fused pyridines active as inhibitors of c-met |
| 07/30/2009 | WO2009093032A1 Phthalazinone derivatives |
| 07/30/2009 | WO2009093029A1 Compounds having crth2 antagonist activity |
| 07/30/2009 | WO2009093026A1 Compounds having crth2 antagonist activity |
| 07/30/2009 | WO2009093018A1 New use for cannabinoids |
| 07/30/2009 | WO2009093013A1 Fused thiophene derivatives as mek inhibitors |
| 07/30/2009 | WO2009093012A1 Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity |
| 07/30/2009 | WO2009093009A1 Fused tricyclic thiophene derivatives as mek inhibitors |
| 07/30/2009 | WO2009092994A1 Novel salt of tegaserod |
| 07/30/2009 | WO2009092993A1 Novel salt of tegaserod |
| 07/30/2009 | WO2009092954A1 Composition containing a retinoid and dispersed benzoyle peroxide |
| 07/30/2009 | WO2009092912A1 Method for the preparation of morphine compounds |
| 07/30/2009 | WO2009092897A1 Compounds for preventing or treating a viral infection |
| 07/30/2009 | WO2009092892A2 Novel composition for treating the side effects of anticancer treatments |
| 07/30/2009 | WO2009092818A1 Abuse resistant melt extruded formulation having reduced alcohol interaction |
| 07/30/2009 | WO2009092810A2 Single pharmaceutical composition containing antibiotics and probiotics |
| 07/30/2009 | WO2009092796A1 Synephrine derivatives for the treatment of cancer |
| 07/30/2009 | WO2009092787A1 Lactylates for the prevention and treatment of infections caused by gram-positive bacteria in animals |
| 07/30/2009 | WO2009092764A1 Compounds comprising a cyclobutoxy group |
| 07/30/2009 | WO2009092720A1 4-phenyl-piperazin-1-yl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 07/30/2009 | WO2009092716A1 Crystalline form of abacavir that is essentially free of solvent |
| 07/30/2009 | WO2009092713A1 Compounds which potentiate the ampa receptor and uses thereof in medicine |
| 07/30/2009 | WO2009092712A1 Compounds which potentiate the ampa receptor and uses thereof in medicine |
| 07/30/2009 | WO2009092642A1 Sulfonamides as orexin antagonists |
| 07/30/2009 | WO2009092602A2 Anti-angiogenic compounds |
| 07/30/2009 | WO2009092601A1 Pharmaceutical dosage form |
| 07/30/2009 | WO2009092581A1 Salt forms of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compositions containing same |
| 07/30/2009 | WO2009092566A1 Substituted amino-benzimidazoles, medicaments comprising said compound, their use and their method of manufacture |
| 07/30/2009 | WO2009092565A1 Substituted tetrahydroimidazopyridine compounds and the use thereof in pharmaceuticals |
| 07/30/2009 | WO2009092516A2 Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects |
| 07/30/2009 | WO2009092442A1 Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways |
| 07/30/2009 | WO2009092432A1 Beta-amino acid derivatives for treatment of diabetes |
| 07/30/2009 | WO2009092431A1 4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidine-2-amine derivatives |
| 07/30/2009 | WO2009092358A1 Induction and promotion of arteriogenesis |
| 07/30/2009 | WO2009092324A1 Oxazolidine derivatives as nmda antagonists |
| 07/30/2009 | WO2009092301A1 Dihydropyridine calcium antagonist compounds, preparation methods and medical uses thereof |
| 07/30/2009 | WO2009092295A1 A set of geldanamycin derivatives and their preparation methods |
| 07/30/2009 | WO2009092293A1 Pyrollidine-based compounds |
| 07/30/2009 | WO2009092284A1 Benzocycloheptene derivatives, preparing processes and pharmaceutical uses thereof |
| 07/30/2009 | WO2009092278A1 Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses |
| 07/30/2009 | WO2009092276A1 Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
| 07/30/2009 | WO2009092170A1 The use of glycosylated antitumor ether lipids to induce and/or enhance autophagy for treatment of diseases |
| 07/30/2009 | WO2009092133A1 Methods for identifying compounds capable of treating or preventing a diabetic complication via set7 or suv39 methyltransferases |
| 07/30/2009 | WO2009092129A1 Delayed release pharmaceutical composition of duloxetine |
| 07/30/2009 | WO2009076170A3 Combinations of therapeutic agents for treating cancer |
| 07/30/2009 | WO2009074674A3 Trisubstituted piperidines as renin inhibitors |
| 07/30/2009 | WO2009074286A3 Pharmaceutical formulation comprising ezetimibe |
| 07/30/2009 | WO2009072807A3 Pharmaceutical composition for preventing or treating fat metabolism-related diseases containing 2-cyclopentene-1-one oxime derivatives |
| 07/30/2009 | WO2009067243A3 Modulation of cd40 expression |
| 07/30/2009 | WO2009065926A3 New anticancer compounds |
| 07/30/2009 | WO2009064861A3 Nitric oxide-releasing diazeniumdiolated polymers, compositions, medical devices, and uses thereof |
| 07/30/2009 | WO2009063248A3 Polymorphic forms of tegaserod glutarate |
| 07/30/2009 | WO2009063222A3 Solid compositions |
| 07/30/2009 | WO2009061786A3 Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists |
| 07/30/2009 | WO2009055331A3 Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 |
| 07/30/2009 | WO2009053737A3 Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders |
| 07/30/2009 | WO2009052411A3 Methods for treatment of thiol-containing compound deficient conditions |
| 07/30/2009 | WO2009050730A3 Rnai mediated knockdown of numa for cancer therapy |
| 07/30/2009 | WO2009050595A3 An improved process for preparing a 2,4-thiazolidinedione derivative |
| 07/30/2009 | WO2009050242A3 Heterocycle-substituted piperazino-dihydrothienopyrimidines |
| 07/30/2009 | WO2009050228A3 Csf-1r inhibitors for treatment of cancer and bone diseases |
| 07/30/2009 | WO2009048594A3 Multicomponent bioactive intravaginal ring |
| 07/30/2009 | WO2009047505A3 Dexanabinol with inhibitors of braf or mek for the treatment of melanoma |
| 07/30/2009 | WO2009047298A3 Dimers of harmol or of its derivatives and uses thereof |
| 07/30/2009 | WO2009045515A3 Antimicrobial and antiviral composition |
| 07/30/2009 | WO2009045488A3 Novel crystalline forms of armodafinil and preparation thereof |
| 07/30/2009 | WO2009034541A3 Controlled release pharmaceutical dosage forms of trimetazidine |
| 07/30/2009 | WO2009034346A3 Anti-bacterial agents |
| 07/30/2009 | WO2009027349A3 Treatment and prevention of neurodegenerative diseases |
| 07/30/2009 | WO2009024980A3 Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors |
| 07/30/2009 | WO2009023356A3 Materials and methods for treating influenza infections |
| 07/30/2009 | WO2009016526A3 Ethers of substituted 5-hydrixy-1h-indol-3-carboxylic acids, a pharmaceutical composition and a method for the production and use thereof |
| 07/30/2009 | WO2009013633A4 Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts |
| 07/30/2009 | WO2009013310A3 Process for preparing 7-alpha-[9-(4,4,5,5,5-pentafluorothiopentyl)nonyl]estra-1,3,5(10)-triene-3,17-beta-diol |
| 07/30/2009 | WO2009009449A8 Phospholipase a2 inhibitors and their use in treating neurological injury and disease |
| 07/30/2009 | WO2009006404A3 Heterocyclic compounds useful as raf kinase inhibitors |
| 07/30/2009 | WO2009002807A3 Indolyl pyrrolidines for the treatment of cancer |
| 07/30/2009 | WO2009002427A3 Methods of synthesizing cinacalcet and salts thereof |
| 07/30/2009 | WO2009000473A3 Effervescent tablets for inhalatory use |
| 07/30/2009 | WO2008157302A3 Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling |